(Q33963958)

30 July 2017

title

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa (English)

1 reference

30 July 2017

0 references

0 references

Paul Lu

13

0 references

Geoffrey S. Gottlieb

object named as

Geoffrey S Gottlieb

1

0 references

James Mullins

17

object named as

James I Mullins

1 reference

30 July 2017

18

Nancy B Kiviat

1 reference

30 July 2017

Robert A Smith

2

1 reference

30 July 2017

Ndeye Mery Dia Badiane

3

1 reference

30 July 2017

Selly Ba

4

1 reference

30 July 2017

Stephen E Hawes

5

1 reference

30 July 2017

Macoumba Toure

6

1 reference

30 July 2017

Alison K Starling

7

1 reference

30 July 2017

Fatou Traore

8

1 reference

30 July 2017

Fatima Sall

9

1 reference

30 July 2017

Stephen L Cherne

10

1 reference

30 July 2017

Joshua Stern

11

1 reference

30 July 2017

Kim G Wong

12

1 reference

30 July 2017

Moon Kim

14

1 reference

30 July 2017

Dana N Raugi

15

1 reference

30 July 2017

Airin Lam

16

1 reference

30 July 2017

Papa Salif Sow for the UW-Dakar HIV-2 Study Group

19

1 reference

30 July 2017

language of work or name

English

0 references

publication date

12 July 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

e22204

1 reference

Creative Commons Attribution 4.0 International

30 July 2017

copyright license

start time

12 July 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Slower heterosexual spread of HIV-2 than HIV-1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort

5 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Are fusion inhibitors active against all HIV variants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Raltegravir treatment response in an HIV-2 infected patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0022204

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

Cellular and plasma viral load in patients infected with HIV-2.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3134476

10.1371/JOURNAL.PONE.0022204

29 October 2018

Identifiers

DOI

1 reference

30 July 2017

0 references

1 reference

30 July 2017

1 reference